MARKSANS PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 166.8 INR | -1.36% |
|
+6.96% | +3.57% |
| Apr. 18 | Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA | MT |
| Feb. 14 | Transcript : Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 21.58B 259M | Sales 2025 * | 26.33B 316M | Capitalization | 75.61B 908M |
|---|---|---|---|---|---|
| Net income 2024 * | 3.34B 40.05M | Net income 2025 * | 4.07B 48.83M | EV / Sales 2024 * | 3.5 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.87 x |
| P/E ratio 2024 * |
22.7
x | P/E ratio 2025 * |
18.6
x | Employees | 852 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Marksans Pharma Limited
| 1 day | -1.36% | ||
| 1 week | +6.96% | ||
| Current month | +0.63% | ||
| 1 month | -4.27% | ||
| 3 months | +4.54% | ||
| 6 months | +21.04% | ||
| Current year | +3.57% |
1 week
158.80
171.25
1 month
152.60177.20
Current year
130.25185.50
1 year
70.55185.50
3 years
38.60185.50
5 years
9.85185.50
10 years
9.85185.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 92-04-15 | |
| Director of Finance/CFO | 54 | 02-09-05 | |
| Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sunny Sharma
BRD | Director/Board Member | 49 | 21-08-10 |
| Chief Executive Officer | 52 | 92-04-15 | |
| Director/Board Member | 52 | 14-09-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 112 M€ | +5.31% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-18 | 166.8 | -1.36% | 415,236 |
| 24-05-17 | 169.2 | +2.61% | 1,606,706 |
| 24-05-16 | 164.8 | 0.00% | 897,429 |
| 24-05-15 | 164.8 | +3.91% | 1,981,296 |
| 24-05-14 | 158.6 | +1.70% | 556,370 |
Delayed Quote NSE India S.E., May 18, 2024 at 03:12 am EDT
More quotes
Marksans Pharma Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The Company produces goods across various therapeutic areas, such as pain management, cough and cold, cardiovascular and central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic, among others. The Company operates four manufacturing facilities across India, the United Kingdom and the United States. The Company manufactures oral solid tablets, soft gelatin capsules and hard capsules in Goa. It also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The Company has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
Sector
Pharmaceuticals
Calendar
2024-05-29
- Q4 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
166.8
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.57% | 908M | |
| +34.35% | 693B | |
| +29.39% | 584B | |
| -3.49% | 372B | |
| +20.15% | 332B | |
| +6.19% | 294B | |
| +14.11% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +9.21% | 168B |
- Stock Market
- Equities
- MARKSANS Stock
